A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

References

1. Bäckhed F., Ding H., Wang T., Hooper L. V., Koh G. Y., Nagy A., Semenkovich C. F., Gordon J. I. 2004; The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101:15718–15723
   [Google Scholar]
2. Calfee D. P. 2008; Clostridium difficile: a reemerging pathogen. Geriatrics 63:10–21
   [Google Scholar]
3. Gill S. R., Pop M., DeBoy R. T., Eckburg P. B., Turnbaugh P. J., Samuel B. S., Gordon J. I., Relman D. A., Fraser-Liggett C. M., Nelson K. E. 2006; Metagenomic analysis of the human distal gut microbiome. Science 312:1355–1359
   [Google Scholar]
4. Gore C., Munro K., Lay C., Bibiloni R., Morris J., Woodcock A., Custovic A., Tannock G. W. 2008; Bifidobacterium pseudocatenulatum is associated with atopic eczema: a nested case-control study investigating the fecal microbiota of infants. J Allergy Clin Immunol 121:135–140
   [Google Scholar]
5. Hardin G. 1960; The competitive exclusion principle. Science 131:1292–1297
   [Google Scholar]
6. Hooper L. V. 2004; Bacterial contributions to mammalian gut development. Trends Microbiol 12:129–134
   [Google Scholar]
7. Lay C., Rigottier-Gois L., Holmstrom K., Rajilic M., Vaughan E. E., de Vos W. M., Collins M. D., Thile R., Namsolleck P. other authors 2005; Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol 71:4153–4155
   [Google Scholar]
8. Louie T. J., Emery J., Krulicki W., Byrne B., Mah M. 2009a; OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 53:261–263
   [Google Scholar]
9. Louie T., Miller M., Donskey C., Mullane K., Goldstein E. J. C. 2009b; Clinical outcomes, safety and pharmacokinetics of fidaxomicin in a phase 2 trial of patients with Clostridium difficile infection. Antimicrob Agents Chemother 53:223–228
   [Google Scholar]
10. Miller M. 2010; Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother 11:1569–1578
    [Google Scholar]
11. Moore W. E. C., Cato E. P., Holdeman L. V. 1978; Some current concepts in intestinal bacteriology. Am J Clin Nutr 31 (Suppl. 10):S33–S42
    [Google Scholar]
12. Rinttilä T., Kassinen A., Malinen E., Krogius L., Palva A. 2004; Development of an extensive set of 16S rDNA-targeted primers for quantifification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 97:1166–1177
    [Google Scholar]
13. Rubin T. A., Gessert C. E., Aas J. 2009; Stool transplantation for older patients with Clostridium difficile infection. J Am Geriatr Soc 57:2386–2387
    [Google Scholar]
14. Shannon-Lowe J., Matheson N. J., Cooke F. J., Aliyu S. H. 2010; Prevention and medical management of Clostridium difficile infection. BMJ 340:c1296
    [Google Scholar]
15. Tannock G. W., Munro K., Bibiloni R., Simon M. A., Hargreaves P., Gopal P., Harmsen H., Welling G. 2004; Impact of consumption of oligosaccharide-containing biscuits on the fecal microbiota of humans. Appl Environ Microbiol 70:2129–2136
    [Google Scholar]